Emergent Stock Analysis

EBS
 Stock
  

USD 20.09  0.77  3.69%   

The big decline in price over the last few months for Emergent Biosolutions could raise concerns from retail investors as the firm is trading at a share price of 20.09 on 479,300 in volume. The company executives failed to add value to investors and position the firm supply of money to exploit market volatility in August. However, diversifying your holdings with Emergent Biosolutions or similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.55. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Emergent Biosolutions partners.
Continue to Investing Opportunities.
  
The Emergent Biosolutions stock analysis report makes it easy to digest most publicly released information about Emergent Biosolutions and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Emergent Stock analysis module also helps to analyze the Emergent Biosolutions price relationship with some important fundamental indicators such as market cap and management efficiency.

Emergent Stock Analysis Notes

About 88.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.74. Some equities with similar Price to Book (P/B) outperform the market in the long run. Emergent Biosolutions recorded earning per share (EPS) of 7.12. The entity had not issued any dividends in recent years. Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats in the United States. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland. Emergent Biosolutions operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. It employs 2416 people. To learn more about Emergent Biosolutions call Daniel AbdunNabi at 240 631 3200 or check out https://www.emergentbiosolutions.com.

Emergent Biosolutions Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Emergent Biosolutions' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Emergent Biosolutions or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Emergent Biosolutions generated a negative expected return over the last 90 days
Emergent Biosolutions has high historical volatility and very poor performance
Over 88.0% of the company shares are held by institutions such as insurance companies
Latest headline from au.finance.yahoo.com: A Emergent BioSolutions Inc. insider increased their holdings by 31 percent last year - Yahoo Finance Australia

Emergent Biosolutions Upcoming and Recent Events

Earnings reports are used by Emergent Biosolutions to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Emergent Biosolutions previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report17th of February 2022
Next Financial Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End17th of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Emergent Biosolutions SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Emergent Biosolutions prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Emergent Biosolutions investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Emergent Biosolutions specific information freely available to individual and institutional investors to make a timely investment decision.
12th of August 2022
Financial Statements and Exhibits. Other Events
View
2nd of August 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Results of Operations and Financial Condition
View
1st of August 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Results of Operations and Financial Condition
View
6th of July 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
7th of June 2022
Termination of a Material Definitive Agreement
View
6th of June 2022
Other Events
View
27th of May 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Submission of Matters to a Vote of Security Holders
View
18th of May 2022
Financial Statements and Exhibits. Entry into a Material Definitive Agreement
View

Emergent Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Emergent Biosolutions is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Emergent Biosolutions backward and forwards among themselves. Emergent Biosolutions' institutional investor refers to the entity that pools money to purchase Emergent Biosolutions' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Blackrock IncCommon Shares8.5 M264.9 M
Vanguard Group IncCommon Shares5.1 M158 M
State Street CorpCommon Shares4.2 M128.8 M
Dimensional Fund Advisors LpCommon Shares1.9 M60.4 M
Earnest Partners LlcCommon Shares1.8 M57.3 M
Jacobs Levy Equity Management IncCommon Shares1.1 M33.7 M
D E Shaw Co IncCommon Shares1.1 M33.1 M
Note, although Emergent Biosolutions' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Emergent Market Capitalization

The company currently falls under 'Mid-Cap' category with total capitalization of 1.14 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Emergent Biosolutions's market, we take the total number of its shares issued and multiply it by Emergent Biosolutions's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Emergent Profitablity

Emergent Biosolutions' profitability indicators refer to fundamental financial ratios that showcase Emergent Biosolutions' ability to generate income relative to its revenue or operating costs. If, let's say, Emergent Biosolutions is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Emergent Biosolutions' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Emergent Biosolutions' profitability requires more research than a typical breakdown of Emergent Biosolutions' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Net Profit Margin of 8.96 %, which may imply that it executes well on its competitive polices and has reasonable control over its expenses and variable costs. This is very large. In the same way, it shows Net Operating Margin of 17.5 %, which entails that for every 100 dollars of revenue, it generated 0.18 of operating income.

Management Efficiency

The entity has Return on Asset of 6.77 % which means that on every $100 spent on asset, it made $6.77 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 10.17 %, implying that it generated $10.17 on every 100 dollars invested. Emergent Biosolutions management efficiency ratios could be used to measure how well emergent biosolutions manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 27th of September, Emergent Biosolutions shows the mean deviation of 2.64, and Coefficient Of Variation of (727.89). Emergent Biosolutions technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We have analyzed nineteen technical drivers for Emergent Biosolutions, which can be compared to its rivals. Please confirm Emergent Biosolutions variance, as well as the relationship between the value at risk and skewness to decide if Emergent Biosolutions is priced favorably, providing market reflects its regular price of 20.09 per share. Given that Emergent Biosolutions has jensen alpha of (0.41), we urge you to verify Emergent Biosolutions's prevailing market performance to make sure the company can sustain itself at a future point.

Emergent Biosolutions Price Movement Analysis

The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Emergent Biosolutions middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Emergent Biosolutions. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
.

Emergent Biosolutions Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Emergent Biosolutions insiders, such as employees or executives, is commonly permitted as long as it does not rely on Emergent Biosolutions' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Emergent Biosolutions insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Dayal Sujata Tyagi over two months ago via Macroaxis 
Acquisition by Dayal Sujata Tyagi of 11852 shares of Emergent Biosolutions subject to Rule 16b-3
Kathryn Zoon over three months ago via Macroaxis 
Sale by Kathryn Zoon of 1173 shares of Emergent Biosolutions
Kathryn Zoon over three months ago via Macroaxis 
Acquisition by Kathryn Zoon of 8446 shares of Emergent Biosolutions subject to Rule 16b-3
Kathryn Zoon over three months ago via Macroaxis 
Sale by Kathryn Zoon of 1996 shares of Emergent Biosolutions
Robert Kramer over three months ago via Macroaxis 
Payment of 1715 shares by Robert Kramer of Emergent Biosolutions subject to Rule 16b-3
Keith Katkin over three months ago via Macroaxis 
Acquisition by Keith Katkin of 8595 shares of Emergent Biosolutions subject to Rule 16b-3
Glessner Coleen over six months ago via Macroaxis 
Emergent Biosolutions exotic insider transaction detected
Jennifer Fox over six months ago via Macroaxis 
Acquisition by Jennifer Fox of 26584 shares of Emergent Biosolutions subject to Rule 16b-3
Katherine Strei over six months ago via Macroaxis 
Acquisition by Katherine Strei of 24164 shares of Emergent Biosolutions subject to Rule 16b-3
Fuad ElHibri over six months ago via Macroaxis 
Emergent Biosolutions exotic insider transaction detected
Richard Lindahl over six months ago via Macroaxis 
Purchase by Richard Lindahl of 3000 shares of Emergent Biosolutions
Robert Kramer over six months ago via Macroaxis 
Sale by Robert Kramer of 32397 shares of Emergent Biosolutions

Emergent Biosolutions Predictive Daily Indicators

Emergent Biosolutions intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Emergent Biosolutions stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Emergent Biosolutions Forecast Models

Emergent Biosolutions time-series forecasting models is one of many Emergent Biosolutions' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Emergent Biosolutions' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Emergent Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Emergent Biosolutions prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Emergent shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Emergent Biosolutions. By using and applying Emergent Stock analysis, traders can create a robust methodology for identifying Emergent entry and exit points for their positions.
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats in the United States. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland. Emergent Biosolutions operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. It employs 2416 people.

Current Emergent Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Emergent analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Emergent analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
62.5Hold4Odds
Emergent Biosolutions current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Emergent analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Emergent stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Emergent Biosolutions, talking to its executives and customers, or listening to Emergent conference calls.
Emergent Analyst Advice Details

Emergent Stock Analysis Indicators

Emergent Biosolutions stock analysis indicators help investors evaluate how Emergent Biosolutions stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Emergent Biosolutions shares will generate the highest return on investment. By understating and applying Emergent Biosolutions stock analysis, traders can identify Emergent Biosolutions position entry and exit signals to maximize returns.
Quick Ratio2.48
Fifty Two Week Low20.77
Revenue Growth-10.30%
Shares Short Prior Month3.36M
Average Daily Volume Last 10 Day673.73k
Average Daily Volume In Three Month626.93k
Shares Percent Shares Out6.85%
Gross Margins40.83%
Short Percent Of Float10.80%
Forward Price Earnings9.07
Float Shares45.16M
Fifty Two Week High55.35
Enterprise Value To Ebitda5.06
Fifty Day Average28.14
Two Hundred Day Average36.54
Enterprise Value To Revenue1.23
Continue to Investing Opportunities. Note that the Emergent Biosolutions information on this page should be used as a complementary analysis to other Emergent Biosolutions' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.

Complementary Tools for Emergent Stock analysis

When running Emergent Biosolutions price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Is Emergent Biosolutions' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Emergent Biosolutions. If investors know Emergent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Emergent Biosolutions listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Emergent Biosolutions is measured differently than its book value, which is the value of Emergent that is recorded on the company's balance sheet. Investors also form their own opinion of Emergent Biosolutions' value that differs from its market value or its book value, called intrinsic value, which is Emergent Biosolutions' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Emergent Biosolutions' market value can be influenced by many factors that don't directly affect Emergent Biosolutions' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Emergent Biosolutions' value and its price as these two are different measures arrived at by different means. Investors typically determine Emergent Biosolutions value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Emergent Biosolutions' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.